# Trial of the efficacy of a second dose of BCG vaccination against tuberculosis (Avaliação da eficácia da segunda dose da vacina BCG em escolares)

Submission date	<b>Recruitment status</b> No longer recruiting	Prospectively registered		
17/01/2007		[X] Protocol		
Registration date	Overall study status	Statistical analysis plan		
21/03/2007	Completed	[X] Results		
<b>Last Edited</b> 15/03/2016	Condition category Infections and Infestations	Individual participant data		

#### Plain English summary of protocol

Background and study aims

The BCG vaccine protects against tuberculosis, a serious infection which affects the lungs. It has also been found to protect against leprosy, an infectious skin and nerve disease. The aim of this study is to assess the effectiveness of a second dose of BCG vaccination against tuberculosis and leprosy.

Who can participate?

Schoolchildren aged 7 to 14 years attending the participating state schools

What does the study involve?

Participating schools are randomly allocated to one of two groups: the intervention group and the control group. Participants in the intervention group schools receive a second BCG vaccination. Participants in the control group schools do not receive the second BCG vaccination. The number of cases of tuberculosis and leprosy are recorded in the two groups.

What are the possible benefits and risks of participating? Not provided at time of registration

Where is the study run from?

767 state schools in the cities of Salvador and Manaus in Brazil

When is the study starting and how long is it expected to run for? June 1996 to June 2016

Who is funding the study?

- 1. The Department For International Development (DFID) (UK)
- 2. Ministry of Health (Brazil)

# Contact information

#### Type(s)

Scientific

#### Contact name

Prof Mauricio Lima Barreto

#### Contact details

Instituto de Saúde Coletiva Universidade Federal da Bahia Rua Basílio da Gama, s/n Campus Universitário Canela Salvador Brazil 40.110-040

# Additional identifiers

#### Protocol serial number

R6715

# Study information

#### Scientific Title

Trial of the efficacy of a second dose of BCG vaccination against tuberculosis (Avaliação da eficácia da segunda dose da vacina BCG em escolares)

#### Acronym

**BCGREVAC** 

# Study objectives

To estimate the efficacy of a second dose of BCG vaccination against tuberculosis and leprosy.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

- 1. Ethical Committee of the University Hospital Professor Edgard Santos (HUPES) of the Federal University of Bahia, 07/10/1996
- 2. National Committee for ethics in Research (Comitê Nacional de Etica em Pesquisa-CONEP), 30 /10/2003, judgement ref: 770/2003, submission ref: 250000.106515/2003-02

# Study design

Cluster randomised trial, with schools being the unit of randomisation. There was no concealment of allocation or intervention and no placebo was used.

#### Primary study design

Interventional

#### Study type(s)

Prevention

#### Health condition(s) or problem(s) studied

Tuberculosis and leprosy

#### Interventions

The intervention was a single intradermal injection with BCG vaccine produced in Brazil using the Moreaux (Rio de Janeiro) strain. This will be a revaccination as children have a high coverage of BCG at birth. The control group will receive no vaccination.

The trial was conducted in two sites, the cities of Salvador and Manaus, in Brazil. Seven hundred and sixty seven state schools were included in the trial. Children in both treatment groups were visited at school to confirm their identification details and their arms were examined for BCG scars. Ascertainment of cases was through the tuberculosis control programme. Cases notified were reviewed independently by two chest physicians, who classified cases into confirmed (microbiological confirmation), probable (would treat based on the information from the records), suspected (no information in the record suggested this was not tuberculosis) and not tuberculosis (excluded from the analysis), and into pulmonary and non-pulmonary forms. A third specialist reviewed those classified differently by the two chest physicians. The validation was blind to vaccination.

Cases were linked to the study population in the study database. Linkage was done blind to vaccination status, based on the name of the child, the name of the mother, the sex and date of birth of the child. All possible matches were reviewed by a member of the study team to assess its reliability. Most were unique matches, with complete concordance on all variables. Home visits to a sample of cases not linked to the database identified only two cases (out of 144 visited) that belonged to the database.

Active informed consent was not obtained. This was because both intervention (BCG revaccination) and absence of intervention were in routine practice in different settings in Brazil at the time, and therefore an "opt out" form of consent was deemed acceptable: parents of children in schools allocated to vaccination were given written information about the vaccine and the trial and offered the opportunity to withdraw their child from the trial.

#### Intervention Type

Biological/Vaccine

# Primary outcome(s)

- 1. Case of tuberculosis
- 2. Case of leprosy

# Key secondary outcome(s))

- 1. Tuberculosis by form
- 2. Leprosy by form

# Completion date

01/06/2016

# **Eligibility**

# Key inclusion criteria

School children aged 7 to 14 years in state schools

# Participant type(s)

Other

# Healthy volunteers allowed

No

# Age group

Child

# Lower age limit

7 years

# Upper age limit

14 years

#### Sex

All

## Key exclusion criteria

- 1. Children with special needs
- 2. Children who received more than one BCG vaccination

#### Date of first enrolment

01/06/1996

#### Date of final enrolment

01/06/2016

# Locations

#### Countries of recruitment

Brazil

# Study participating centre Universidade Federal da Bahia

Salvador Brazil 40.110-040

# Sponsor information

#### Organisation

Institute for Collective Health (Instituto de Saúde Coletiva) (Brazil)

#### **ROR**

https://ror.org/03k3p7647

# Funder(s)

#### Funder type

Government

#### **Funder Name**

Department for International Development

#### Alternative Name(s)

Department for International Development, UK, DFID

#### **Funding Body Type**

Government organisation

#### **Funding Body Subtype**

National government

#### Location

United Kingdom

#### **Funder Name**

Ministry of Health (Brazil)

# **Results and Publications**

Individual participant data (IPD) sharing plan

#### IPD sharing plan summary

Not provided at time of registration

#### **Study outputs**

Output type Details Date created Date added Peer reviewed? Patient-facing?

Results article results 01/11/2001 Yes No

results

Results article		01/04/2003		Yes	No
Results article	results	01/04/2003		Yes	No
Results article	results	01/12/2004		Yes	No
Results article	results	01/10/2005		Yes	No
Results article	results	08/10/2005		Yes	No
Results article	results	24/06/2014		Yes	No
Protocol article	protocol	01/10/2002		Yes	No
<u>Protocol article</u>	protocol	01/03/2004		Yes	No
Participant information sheet	Participant information sheet	11/11/2025	11/11/2025	No	Yes